LEHI, Utah, Dec. 8, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company, today presented new clinical data from its Phase 2a study of ofirnoflast (HT-6184) at the 67th ...
LEHI, Utah, Dec. 10, 2024 /PRNewswire/ -- Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today ...
The MarketWatch News Department was not involved in the creation of this content. - Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic ...
Halia Therapeutics has completed the enrolment in its Phase IIa trial of HT-6184 (Ofirnoflast) in those with lower-risk myelodysplastic syndrome (MDS). The two-stage trial is designed to test the ...
New CSO & GM role underscores Halia's commitment to resilience-based therapeutic development and advances collaboration with the Department of Health – Abu Dhabi The Genetic Resilience Company ...
(MENAFN- PR Newswire) LEHI, Utah, Dec. 13, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat ...
European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events in ESA-refractory ...
Industry leaders join at a pivotal moment as company advances HT-6184 toward a pivotal trial in MDS and prepares Phase 2a initiation for HT-4253 in Alzheimer's disease The expanded board joins Halia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results